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ABSTRACT  
Background 
Cancer is a proliferation disease affecting a genetically unstable cell population, in which molecular alterations can 
be somatically inherited by genetic, epigenetic or extragenetic transmission processes, leading to a cooperation of 
neoplastic cells within tumoral tissue. The efflux protein P-glycoprotein (P-gp) is overexpressed in many cancer cells and 
has known capacity to confer multidrug resistance to cytotoxic therapies. Recently, cell-to-cell P-gp transfers have been 
shown. Herein, we combine experimental evidence and a mathematical model to examine the consequences of an 
intercellular P-gp trafficking in the extragenetic transfer of multidrug resistance from resistant to sensitive cell 
subpopulations. 
Methodology and principal findings 
We report cell-to-cell transfers of functional P-gp in co-cultures of a P-gp overexpressing human breast cancer 
MCF-7 cell variant, selected for its resistance towards doxorubicin, with the parental sensitive cell line. We found that P-
gp as well as efflux activity distribution are progressively reorganized over time in co-cultures analyzed by flow 
cytometry. A mathematical model based on a Boltzmann type integro-partial differential equation structured by a 
continuum variable corresponding to P-gp activity describes the cell populations in co-culture. The mathematical model 
elucidates the population elements in the experimental data, specifically, the initial proportions, the proliferative growth 
rates, and the transfer rates of P-gp in the sensitive and resistant subpopulations.  
Conclusions 
We confirmed cell-to-cell transfer of functional P-gp. The transfer process depends on the gradient of P-gp 
expression in the donor-recipient cell interactions, as they evolve over time. Extragenetically acquired drug resistance is an 
additional aptitude of neoplastic cells which has implications in the diagnostic value of P-gp expression and in the design 
of chemotherapy regimens 
 
 
1. INTRODUCTION 
Current view on cancer  
In essence, cancer is a proliferation disease affecting a 
genetically unstable cell population. The somatic 
mutation theory, which is the prevailing paradigm, 
stipulates that cancer arises from a stepwise 
accumulation of changes in genes that progressively 
drives subclonal neoplastic cells to evolve 
independently from the others, escaping from 
proliferation control and competing for space and 
resources and, finally, to kill the host. The key feature is 
that the cancer-promoting changes are intrinsic 
molecular events that are i) inheritable by daughter cells 
and ii) selectable, in the sense that they confer selective 
advantage in the cell population environment [1, 2]. It is 
also widely recognized that genetic instability results in 
the creation of diverse daughter cells, capable of 
interaction with the cell microenvironment, conferring 
to the tumor the properties of a heterogeneous tissue [3].  
Within such tumor tissue, molecular alterations are 
considered to be somatically inherited by genetic, 
epigenetic (traits that are not dependent on the primary 
sequence of DNA) or extragenetic (post-translational 
protein modifications that initiate and support positive 
feedback loops) transmission processes [1], leading to a 
cooperation of neoplastic cells [4]. 
Role of P-glycoprotein in breast cancer 
Despite decades of research, breast cancer remains a 
major public health issue. Worldwide, breast cancer 
represents 23 % of overall female cancers and accounts 
for 40,000 deaths each year in the United States alone. 
Currently, the lifetime risk of developing a breast cancer 
for women born in the United States is 1 in 8. For 
metastatic forms of breast cancers, the 5-year relative 
survival is only 26 % [5] and complete remission has 
been estimated as low as 3.1 % after this period [6]. 
Response to first-line chemotherapies span from 30 to 65 
% and are followed, after a period varying from 6 to 10 
months, by disease progression [7]. In fact, resistance to 
chemotherapy is believed to cause treatment failure in 90 
% of metastatic breast cancer patients [8].  
Resistance to chemotherapy is related to the overall 
mechanisms that are involved in a decrease of drug 
efficacy upon tumors [9]. Among these factors, proteins 
lowering the intracellular concentration of 
chemotherapeutics and belonging to the ATP-binding 
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Cassette (ABC) transporters are well-known for their 
specific responsibility [10]. These membrane proteins 
are characterized by their ability to efflux a large panel 
of both chemically and functionally unrelated 
compounds comprising potent cytotoxics currently used 
in chemotherapeutic treatments. Consequently, tumors 
overexpressing this type of energy-dependent pump 
have been very early identified on the basis of their 
Multi-Drug Resistance (MDR) phenotype [11]. The P-
glycoprotein (P-gp) was the first drug-efflux protein 
characterized [12]. With the growing number of 
molecularly cloned ABC transporters (48 different 
genes up to now have been identified in the human 
genome), a rational nomenclature have been proposed. 
Meta-analysis [13] or immunochemistry studies [14] 
have determined that approximately 40 % of all breast 
cancer tumors express ABCB1/MDR1 coded P-gp. 
ABCB1/MDR1 gene expression has a prognostic value 
for cell resistance to anticancer drugs [15, 16] and for 
treatment failure [17].  
Genetic versus extragenetic resistance transmission 
Until now, the development of multi-drug resistance 
in neoplastic cells was explained as the consequences of 
two main mechanisms. On one hand, cells natively 
expressing drug-efflux proteins conserve their 
phenotype throughout the process of malignant 
transformation. On the other hand, in non-expressing 
cells, chemotherapeutics have been shown first to 
induced P-gp expression and, second, to exert a 
selection of resistant cells during the course of 
chemotherapy [18-21]. Therefore, P-gp induction was 
considered to be only dependent on the cell type and/or 
the previous history of exposure to cytotoxics. 
Biomathematical models have been proposed to 
describe the kinetics of P-gp induction as a function of 
tissue cytotoxic concentration [22] with the objective of 
adapting the time course of drug administration to 
overcome as much as possible multidrug resistance. 
Recently however, extragenetic transmissions of 
multidrug resistance have been reported. These 
unexpected events all involve direct transfers of P-gp to 
ABCB1/MDR1 non-expessing recipient cells from 
various multidrug resistance donors, namely adherent 
cell lines in vitro and in vivo [23], stromal cells isolated 
from patients suffering of ovarian cancers [24] and  
lympblastic leukemia cells in suspension [25]. These 
findings actually add a new modality of resistance 
appearance, and possibly spreading, in a population of 
tumor cells. Theoretically, cell-to-cell P-gp transfers in 
conditions of antineoplastic treatment could confer a 
significant advantage to sensitive cells, keeping them 
alive long enough to produce their own P-gp copies, 
under the induction process, and thus, to resist 
chemotherapy. However, the real dynamics of 
extragenetic acquired resistance in a growing population 
of cancer cells remains, up to now, unknown. Herein, 
we propose a biomathematical model, derived from a 
previous analysis [26], supported with experimental 
parameters and combining processes of i) cell 
proliferation and death, ii) P-gp induction and 
degradation and iii) cell-to-cell P-gp transfer, to help 
answer this question. The present model was supplied by 
new data obtained in vitro from MCF-7 human breast 
adenocarcinoma and capable of intercellular P-gp 
transfer [23]. Comprehensive mechanistic aspects of 
cell-to-cell P-gp transfers are presented in a companion 
paper [27]. The main objectives of the present work were 
to investigate the influence of both cancer cell line 
intrinsic factors (growth rate, initial proportions of 
sensitive and resistant cells, and P-gp transfer rate), as 
well as treatment management parameters (i.e. cycles of 
drug administration), on overall multidrug resistance, 
both genetically and extragenetically transmitted. 
  
2. MATERIAL AND METHODS 
2.1. Cell lines. 
The cell lines used in the present study were the wild-
type drug-sensitive human breast adenocarcinoma 
MCF-7, purchased at the American Type Culture 
Collection, and a multi-drug resistant MCF-7/DOXO 
variant, kindly provided by Pr. J.-P. Marie (Hôtel Dieu, 
Paris, France).  The cells were grown in RPMI 1640 
medium supplemented with 5% heat-inactivated fetal 
bovine serum, 2 mM L-glutamine, and 1% 
antibiotic/antimycotic solution. Doxorubicin (1 µM) was 
added to the culture medium for the maintenance of the 
multi-drug resistant phenotype of MCF-7/doxo cells. 
Cultured cells were incubated at 37°C under a water-
saturated 95% air-5% CO2 atmosphere. Exposure of 
MCF-7/DOXO to the P-gp inhibitors verapamil or 
cyclosporine A dose-dependently abolished both 
resistance to doxorubicin and P-gp activity in MCF-
7/doxo [28].  
For proliferation assays, cells were plated at 105 
per 60 X 15 mm tissue culture dish with or without 
doxorubicin. Cells were dissociated by treatment with 
trypsin/EDTA and then counted in a Malassez chamber. 
Cell proliferation was followed every 12 hours during 
six days.  
2.2. Analysis of P-gp expression and activity by flow 
cytometry.  
Cultured or co-cultured MCF-7 were trypsin-
resuspended and washed with HBSS before analysis. For 
intercellular P-glycoprotein transfer studies, P-gp was 
labelled using a phycoerythrin (PE)-conjugated UIC2 
mAb (Beckman Coulter France, Villepinte, France). The 
fluorescent light (FL) was quantified using a Cell Lab 
Quanta SC MPL flow cytometer (Beckman Coulter) 
equipped with a 22 mW 488 nm excitation laser. Voltage 
settings of photomultipliers were not modified 
throughout the experiments. Each analysis consisted in a 
record of 10 000 events, triggered on electronic volume 
(EV) as primary parameter, according to a particle 
diameter exceeding 8 µm. Red fluorescence was 
measured in FL2 channel (log scale) through a 575 nm 
band pass emission filter. More than 93.1 ± 0.4 % (mean 
± S.E.M.) of gated events exhibited a FL2>1 for MCF-
7/DOXO.  
To study P-gp activity, resuspended cells were 
loaded with 0.25 µM calcein acetoxy-methylester 
(Invitrogen Life Technologies, Carlsbad, CA) in RPMI 
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for 15 min at 37°C in the dark. Green FL was quantified 
via the FL1 channel (log scale) through a 525 nm band 
pas filter. Controls of MCF-7, MCF-7/DOXO and 
extemporaneous mixtures of 50:50 MCF-7: MCF-
7/doxo were analysed before co-cultures, in all 
experiments.  
2.3. Analysis of P-gp by flow cytometry transfer in 
tagged MCF-7.  
75 %-confluent sensitive MCF-7 were loaded with 25 
µM of the cell-permeant reactive fluorescent dye 
CellTracker Blue 4-chloromethyl-6,8-disulforo-7-
hydroxucoumarin (Invitrogen Life Technologies, 
Carlsbad, CA) for 2 hour at 37°C in 25 cm² culture 
dishes. The cells are then washed twice with HBSS and 
covered with fresh complete culture medium. Either 
CellTracker Blue loaded sensitive MCF-7 (ctbMCF-7), 
or MCF-7/doxo, or a carefully homogenized 50:50 
mixture of ctbMCF-7:MCF-7/doxo were plated at the 
desired density on 60mm culture dishes and analysed by 
flow cytometry after labelling using the PE-conjugated 
UIC2 mAb, as described before. 
2.4.Flow cytometry data conditioning.  
Accurate fitting of the mathematical model to flow 
cytometry all-events histograms required raw data noise 
reduction. Thus, list-mode data were segregated into 
binned logarithmic histograms, with a bin width of 0.05 
in log scale of arbitrary fluorescence units. The 
distributions were normalized, by scaling to an integral 
area of 1.0, in order to obtain a density of probability. 
2.5. Mathematical model of P-gp activity transfer.  
In this section, we describe a mathematical model that 
has been developed and used to describe the 
consequences of a cell-to-cell P-gp protein transfer in 
terms of multidrug resistance activity. Herein, the 
resistance activity is viewed as the ability of a cell to 
efflux cytotoxics, which is considered to be correlated to 
the number of P-gp copies within the cell membrane. 
We decompose the construction of the model by 
considering separately the process of i) cell proliferation 
and death, ii) P-gp induction and degradation rate, both, 
at the cell and the population level, and iii) P-gp transfer 
between cells.  We consider p the P-gp efflux activity of 
a cell, functionally measured by the loss of calcein 
fluorescence for a resistant cell compared to a sensitive 
one, and we introduce u(t,p) the density of cells at time t 
having a P-gp activity p. In the sequel, for a given cell, 
the fluorescence p is assumed to be a function of P-gp 
expression on the cell surface.   
The terminology “density of cells with respect to p” 
means that, if p1  p2 are two quantities of P-gp 
activity, then the number of cells with a P-gp activity in 
between p1  p2 at time t is  
u(t, p)dp
p1
p2 . 
According to the fluorescence scale used in cytometry, p 
varies between pmin=1 and pmax=104, and the total 
number of cells is given by 
U(t)  u
pmin
pmax (t, p)dp. 
In order to describe the time course of the cell 
distribution, we introduce the following model which has 
already been described in [26] 
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In this model, the diffusion term describe a stochastic 
drift of P-gp activity (with no bias), while the convection 
term describes an oriented drift of the activity of P-gp, 
and the proliferation term combines the cell division and 
mortality of cells, which is assumed to depend on the 
activity p of P-gp only during the treatment. Robin type 
boundary conditions are introduced to preserve the total 
number of individuals when only the drift process takes 
place (i.e. =0 and =0). The term describing transfer of 
P-gp has been presented in detail in [26]. The parameter 
 describes the time between two consecutives transfers, 
and the transfer of operator T is defined by 
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where  extends   by 0 outside of the interval (1,104). 
The main idea in the construction of the transfer operator 
T is to derive the probability of a recipient partner to 
acquire a level p of P-gp in a transfer event from all 
possible donor partners. To describe a transfer event we 
use the following rule: if a cell C1 and a cell C2 have, 
respectively, a quantity p1 and p2 of P-gp activity before 
transfer, then, after transfer, C1 (respectively, C2) will 
have an activity p1-f(|p1-p2|)(p2-p1) (respectively, p2-f(|p1-
p2|)(p1-p2) ). So the fraction transferred is f(|p1-p2|), 
which depends on the absolute value of the difference 
between p1 and p2 (the distance between the P-gp 
activities of C1 and C2). The model is used with 
constraints that correspond to a permissible interval 
(min,maxfor |p1-p2| to allow transfer. As a 
consequence, when |p1-p2|<min or |p1-p2|>max there is 
no transfer (i.e. f(|p1-p2|) = 0) and otherwise a constant 
fraction is transferred (i.e. f(|p1-p2|) =). Therefore, the 
parameter 0 is called the transfer efficiency 
andmin<max are called the transfer thresholds.  
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3. RESULTS 
 
3.1. MCF-7 proliferation and resistance.  
In 2005, Levchenko et al. have shown that several drug 
sensitive cell lines, including the well-established 
human breast adenocarcinoma cells MCF-7, are able to 
acquire multidrug resistance extragenetically, via a 
direct intercellular transfer of the resistance protein P-gp 
from a derived mdr1-transfected cell line. In the present 
work, the consequences of P-gp transfers in MCF-7 
were studied by using, as a P-gp donor, a cell line 
variant obtained by selection for resistance to 
doxorubicine (DOXO) and therefore called MCF-
7/DOXO. MCF-7/DOXO have previously been shown 
to overexpress P-gp, to resist to doxorubicin and to 
efflux P-gp-substrate fluorescent probes in a verapamil 
and cyclosporine A-sensitive manner [28]. 
 
Resistance phenotypes were first assessed both in 
MCF-7 and MCF-7/DOXO by determining growth rates 
in the presence of increasing DOXO concentrations (0, 
0.1, 0.3, 1, 3 and 10 µM). As seen in Figure 1, without 
treatment, MCF-7 and MCF-7/DOXO displayed very 
similar growth rates, 0.6195 and 0.6328 per day, 
respectively. These values correspond to a doubling 
time of 26.8 and 26.3 hours, for sensitive and resistant 
cells, respectively. In the presence of DOXO (0.1-3 
µM), the proliferation rates of MCF-7/DOXO were not 
significantly modified. By contrast, MCF-7 cells were 
strongly affected by the treatment, the growth rates 
passing through 0.0316 per day at 0.1 µM DOXO and 
decreasing very rapidly to -0.7492 per day with 3 µM 
DOXO.  
 
 
3.2. Transfers of P-gp and efflux activity in co-cultures.  
In order to investigate potential transfers of P-gp 
between cells, 50 % of non P-gp-expressing parental 
MCF-7 cells were co-cultured with 50 % of their 
multidrug resistant counterpart MCF-7/DOXO. Obvious 
morphological differences allow distinction of MCF-7 
from MCF-7/DOXO variants in the monolayer under 
phase contrast microscopy (Figure 2). After attachment 
to the tissue culture treated dish, MCF-7 were 
characterized by markedly birefringent membrane 
margins, while MCF-7/DOXO were more spread with 
dark edges and flat cell bodies.  Following several days 
of growing in co-culture, we noticed a singular and 
stable spatial organization consisting in the formation of 
MCF-7 islets encased in a layer of MCF-7/DOXO.  
 
A first approach used to detect a potential intercellular 
P-gp transfer was direct immunodetection of P-gp in 
living cells in the co-cultures, by using a phycoerythrin-
conjugated monoclonal antibody directed against an 
epitope localized in an extracellular loop of the protein 
[29]. Membrane P-gp content was followed over time, 
from day 0 to day 6, by flow cytometry. As shown in 
Figure 3A, the peak corresponding to non P-gp-
expressing MCF-7 at day 0 progressively drifted to the 
right, towards the regions of high P-gp levels, with time 
in co-culture. In addition, the total mass of P-gp 
remained unchanged over time for 10,000 analyzed cells 
(Figure 3C). Thus, it is suggested that that the 
distribution of P-gp within the cell population was 
reorganized with time but that the balance between P-gp 
biosynthesis and degradation remained constant, in 
average, in the samples. 
Figure 1. Proliferation and resistance of MCF-7 variants in culture.  
Growth curves of MCF-7 (A) and MCF-7/DOXO (B) were established over 5,5 days. Cells were grown in the 
absence or presence of doxorubicin (0.1 to 10 µM, corresponding symbols given in the legend in B) and counted 
every 12 hours in a Malassez chamber. Cell counts are expressed as the logarithm of the cell numbers at various times 
(N) divided by the cell number at day 0 (N0). 
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To investigate whether P-gp transfers generate a 
functional drug resistance, the ability of co-cultured 
cells to efflux calceinAM, a P-gp substrate probe which 
is a precursor of the fluorescent dye calcein was 
assayed, again by flow cytometry. In these experiments, 
cell fluorescence accumulation is therefore an inverse 
function of P-gp activity. Symmetrically to what 
observed with membrane P-gp content, the peak of 
fluorescence corresponding to initially sensitive cells, 
with a high calcein concentration, was also 
progressively shifted, but to the left, towards regions of 
less fluorescence accumulation (Figure 3B). These cells 
therefore acquired an aptitude to efflux the fluorescent 
dye. However, by contrast with Figure 3A, the activity 
distribution is additionally characterized by the 
appearance of a third subpopulation displaying an 
intermediate efflux activity. This middle peak increased 
in amplitude with time. Concurrently, the peak 
amplitudes corresponding to the subpopulations of 
MCF-7 with higher and, especially, lower calcein 
concentrations slightly declined. Interestingly, the total 
mass of activity (Figure 3D) also remained constant 
with time.  
 
 
 
Although the progressive shift towards regions of 
higher membrane P-gp content, concurrently with the 
appearance of higher efflux activities, are observations 
that can be accounted for by effective P-gp transfer in 
co-cultures, the exact origin of these protein and activity 
redistributions had to be clarified. It should be first 
mentioned that, in our experiments, such phenomena are 
never observed in cells cultured separately. Nevertheless, 
in co-cultures, various cell interactions, secretion of 
soluble factors, could be responsible for 
microenvironmental regulations resulting in a decrease 
in P-gp expression in MCF-7/DOXO. Such phenomena 
could result in P-gp and activity redistributions, 
consistent with results observed in the preceding 
experiments. To investigate these points, it was 
necessary to distinguish and to follow both MCF-7 
variants in co-cultures. Thus, parental sensitive MCF-7 
cells were tagged with the persistent dye Cell Tracker 
Blue (ctbMCF-7) before mixture with MCF-7/DOXO 
and co-culture.  As seen in Figure 4, upon one day of co-
culture, a population of ctbMCF-7 appeared also positive 
to P-gp detection with the phycoerythrin-conjugated 
UIC2 mAb. This population appeared to be relatively 
stable over 3 days of co-culture, even though dilution of 
Celltracker blue within successive ctbMCF-7 generations 
weakened the signal and did not allow us to distinguish 
cell subpopulations further. In these experiments we also 
noticed continuous variation of phycoerythrin 
fluorescence in co-cultured ctbMCF-7, suggesting a 
progressive acquisition of P-gp by sensitive parental 
MCF-7, rather than a decrease of P-gp expression in 
MCF-7/DOXO. The possibility that dual positive events 
were, in fact, artifactual doublets of ctbMCF-7+MCF- 
Figure 2. Spatial organization of MCF-7 and MCF-7/DOXO in co-cultures.  
To obtain phase contrast micrographs of growing MCF-7 variants in co-cultures, dishes were seeded with a 50:50 mixture of MCF-
7:MCF-7/DOXO at day 0. Morphological differences permit an immediate identification of each cell subpopulation. MCF-7 appeared 
birefringent and round (boxes) whereas MCF-7/DOXO are more flat and spread (ellipses). Note that the cells remained organized in 
well-delimited islets. 
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7/DOXO can be excluded because the cytometry 
Figure 3. Flow cytometry analysis of P-gp and efflux activity transfers between MCF-7 and MCF-7/DOXO variants of the human breast 
cancer cell line.  
A-B, A 50:50 MCF 7:MCF 7/DOXO cell mixture was seeded on cultures dishes at day 0 and co-cultured. P-gp expression was immunodected by 
using a PE-conjugated UIC2 monoclonal antibody (A) and P-gp activity was followed with calceinAM as a fluorescent probe (B) after 0, 3, 4, 5 and 
6 days of co-culture. In both cases (A & B) a sample of 10 000 cells was analyzed. In order to reduce the stochastic fluctuations, normalized binned 
logarithmic histograms were built from all-events list-mode raw data (see methods). In A, the peak (on the left side) of MCF-7 expressing low 
levels of P-gp corresponds to the sensitive cells. The peak on the right side corresponds to MCF-7/DOXO resistant cells. In B, the peak (on the right 
side) corresponds to the low efflux activity of sensitive MCF-7 cells, and the peak on the right corresponds to the MCF-7/DOXO resistant cells. C-
D, total mass (sum of collected fluorescence light of a sample) of P-gp (C) and efflux activity (D) in co-cultures have been computed through days 
0, 3, 4, 5 and 6 for 10 000 events analyzed by flow cytometry. 
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analysis was triggered on the electronic Coulter-type 
cell volume (EV). Cell diameters in quadrants Q1, Q2 
and Q4 matched to values corresponding to lone MCF-7 
or MCF-7/DOXO cells (Figure 5).  
 
 
Taken together, these results strongly suggest the 
occurrence of a mechanism of transfer i) involving only 
a small fraction of the membrane content in protein of 
the donor cells but conferring a significant efflux 
activity to the recipient cells and ii) exhibiting a 
continuous exchange mode simply dependent on the 
gradient, i.e. the net difference in P-gp expression levels 
separating the cells under concern. In order to test these 
hypotheses and to evaluate their consequences in the 
dynamics of multidrug resistance within a cell culture, a 
mathematical transfer model was developed.  
 
3.3. Estimation of transfer parameters.  
To quantify the transfer of P-gp activity, which is 
assumed to result in a gain of resistance, we have used a 
mathematical model, presented in the material and 
methods section and derived from Hinow et al. (2009), 
with no-random noise (i.e. =0), and without efflux 
activity drift (i.e. h=0). These terms were neglected, 
since a short-term (6 days) period was considered here, 
while these terms were introduced to describe a long-
term evolution of the cell culture (i.e. a period of 
months). In addition, in the absence of cytotoxics and 
according to Figure 1, the growth rate is independent of 
the P-gp content. Herein, the growth rate was thus 
assumed to be identical for MCF-7 and MCF-7/DOXO 
in co-culture (ρ=0.63 day-1).   
The transfer rate , the transfer efficiency f, and the 
thresholds min < max were estimated by using intensive 
parameter estimation computations. The conditioned 
flow cytometry activity distribution at day 0 was used as 
an input for the numerical simulation of the model. The 
best fit to data distribution at day 6 was estimated by 
using the least square minimization method over 100,000 
different values of the parameters (Figure 6).  
Conclusively, the model is coherent with the existence of 
cell-to-cell resistance transfers, since the best fit of the 
parameters gives  and f =0.2, corresponding to 
non-null transfer rate and efficiency.  The parameters of 
Figure 4. Flow cytometry detection of P-gp transfers in tagged parental MCF-7.  
Parental sensitive MCF-7 were tagged with the persistent fluorescent probe CellTracker Blue (ctbMCF-7), prior to co-cultures. ctbMCF-7 
alone, extemporaneous mixtures of 50:50 ctbMCF-7:MCF-7/DOXO or co-cultures at various times were analyzed after labelling with the 
PE-conjugated UIC2 monoclonal antibody. Scatter plots were obtained by quantifying CellTacker Blue content the FL1 channel and P-gp 
immunodetection in the FL2 channel. A, pure ctbMCF-7. B, pure MCF-7/DOXO. C, extemporaneous mixture of ctbMCF-7:MCF-
7/DOXO.  D-F, co-cultures obtained from 50:50 ctbMCF-7:MCF-7/DOXO, after 1 to 3 days. All analysis were performed with 
unchanged excitation light power and photomultipliers voltage settings. The quadrant limits were set in order to obtain less than 1 % of 
double positive cells (Q2) in the analysis of the sample C. Despite a progressive loss of FL1 signal, due to Celltracker blue dilution within 
daughter ctbMCF-7, a population of dually labelled cells appeared in the upper right quadrant. Percentages indicate the fraction of cells 
having a double positive labelling in quadrant Q2. 
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the model, the respective methods used to determine 
their numerical values and the associated symbols are 
given in Table 1.  
 
Fitted parameters seem to indicate that some 
limitations, or constraints, occurred for transfers 
between cells in our experimental conditions. First, the 
transfers were not homogeneous over the whole 
assortment of activities expressed by cells within the co-
cultures. In this respect, a threshold min distinct from 0 
suggests that transfers did not occur or were not 
detected when P-gp activities of the cells were to close. 
In addition, since the threshold max is not equal to the 
maximal value 104, transfers did not arise either in case 
of extreme activity differences. This implies the 
occurrence of a permissible range of activities 
governing the optimal transfers between donor and 
recipient cells. Moreover, a transfer rate of  means 
that transfer events occurred in average every 1/  
days for each cell in our experiments. Finally, the 
quantity of transferred activity globally corresponds to a 
fraction f =0.2 of the difference between the activity of 
the donor and recipient cell.   
 
3.4. Consequences of resistance activity transfers on 
model response to chemotherapeutic cycles in co-
cultures.   
Fast acquisition of P-gp activity by doxorubicin-
sensitive MCF-7 in a population of growing tumoral 
cells may be of first relevance to determine the 
dynamics of response to chemotherapy. Thus, to test the 
significance of P-gp transfers within a co-culture of 
sensitive and resistant cells, simulations were carried out 
by using our mathematical model of activity transfers, 
fed with biological data.  
Herein, the simulations were built with basic 
parameters determined in vitro, in particular the growth 
rates of monolayers and the transfer parameters. 
Therefore, cell proliferation was artificially high in 
abstraction of any physiological environment and the 
growth curves obtained by simulation should not be 
considered as data clinically exploitable. Likewise, 
pharmacokinetics of doxorubicin (such as elimination 
half-life, drug clearance, volumes of distribution) was 
ignored. The simulated treatment was simplified into a 
bolus of 1 µM doxorubicin that reaches the maximum 
concentration in the extracellular compartment with no 
delay and maintains the same level over 10 days. Then, 
the treatment was interrupted for 4 days (i.e. doxorubicin 
concentration is zero). The treatment cycled every 14 
days for 4 cycles.  
As shown in Figure 7A, the number of pure 
sensitive MCF-7 in a simulated culture declined 
progressively in the presence of DOXO during the first 
10 days of a treatment cycle and, thereafter, increased 
during the 4-days interruption at rates ρ(pmin) 
corresponding to the values previously determined 
(Figure 1). To follow the respective populations of 
sensitive and resistant cells within the simulated co-
cultures, a particular attention should be paid to the 
criterion used to define what exactly a sensitive cell is 
(resistant cells being considered as the complement). 
Herein, we defined sensitive cells as MCF-7 having a 
negative growth rate in the presence of 1 µM 
doxorubicin. The growth rate ρ is supposed to vary only  
Figure 5. Distribution of cell diameters in parental sensitive, multidrug resistant and transferred MCF-7 populations.  
The histograms correspond to cell diameters in quadrants Q1 (CellTracker Blue positive cells, left), Q4 (UIC2 positive cells, middle) and Q2 
(double positive cells, right) of Figure 4. Quantitative values give cells volumes of 1984 ± 51 µm3 for parental sensitive MCF-7, 1776 ± 41 
µm3  for multidrug resistant MCF-7/DOXO and 2398 ± 39 µm3 for transferred MCF-7 (mean ± coefficient of variation). 
Table 1.  List of the model parameters, their significations, values and symbols.  
The column method refers to the approach employed to determine their respective numerical value 
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as a function of the overall P-gp activity p (intrinsic 
activity and activity acquired or lost by transfers), as 
presented in supporting Figure 7B. As a consequence, 
transferred sensitive cells with enough P-gp activity to 
have a positive growth rate will be considered as 
resistant cells.   
 
 
The evolution of the simulated co-cultures was 
extremely dependent on the initial distribution of cells, 
i.e. the relative proportions of cells of with different P-gp 
contents. Again, as for the estimation of transfer 
parameters, the biological data distribution in term of 
efflux activity p at day 0, was used as an input template 
for computer simulations. However, the simulations 
were started with inocula of 104 cells (corresponding to 
Figure 6. Estimation of parameters for the transfer model.  
This graph corresponds to the distribution of P-gp activity at day 6 of co-culture. The initial distribution of P-gp activity at day 0 (not shown 
here) was obtained from a mixture of 50:50 MCF-7:MCF-7/DOXO cells analyzed by cytometry as in Figure 4. The transfer model was run 
over 6 days. The dotted curve corresponds to the efflux activity of the co-culture measured at day 6, and the solid curve corresponds to the 
distribution of activity derived from model. The fitting parameters are given above the curves and were obtained by least squares 
minimization.   
Figure 7. Growth rate of sensitive cell as a function of P-gp content.  
A, computer simulation giving the number of sensitive MCF-7 versus time during a chemotherapy regimen, cycling every 14 days, with 10 
days of 1 µM doxorubicin treatment followed by 4 days of interruption, for 4 cycles. The initial simulated tumor consisted in 104 MCF-7 
having growth rates corresponding to ρ(pmin). B, plot giving the growth rates ρ as a function of the P-gp-driven calceinAM efflux activity p 
for cells exposed to 1 µM doxorubicin. The function describing ρ(p) is used in the simulations presented Figure 8. All cells having a negative 
growth rate are considered as sensitive MCF-7. 
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an approximate mass of 0,01 mg) comprising only a 
small proportion of resistant cells, 0.1 % (i.e. 10 cells, 
Figures 8A&B), or 1 % (i.e. 100 cells, Figures 8C&D). 
For each condition, the numbers of sensitive, resistant 
and total cells were plotted as a function of time in two 
situations: without or with cell-to-cell P-gp activity 
transfers. 
In the absence of transfer (Figure 8A&C), resistant 
cells grew linearly, and represent after few days the 
majority of the cells in the co-cultures. The number of 
sensitive cells decreased during the treatment and 
increased during the interruption phases. In these 
simulations, the initial distribution of sensitive cells was 
based on low efflux activities analyzed by flow 
cytometry. As a consequence, the population of 
sensitive cells did not correspond to a single ray but was 
rather represented by a bell curve shape encompassing a 
spectrum of efflux activities, from zero to several 
arbitrary fluorescent units. Consequently, from a cycle 
to another, the sensitive cells having the less negative 
growth rates were selected by the treatment.  For that 
reason, the population of sensitive cells decreased to a 
minimum and, then, increased again by growing during 
treatment interruptions while the growth rates converged 
to zero during the doxorubicin phases.  
In the presence of transfers (Figure 8B&D), results 
differed from above and were greatly influenced by the 
initial number of resistant cells in the inoculum. In fact, 
with transfers during treatment, growth rates of resistant 
and sensitive cells converged to an intermediate value, 
due to a loss of activity by resistant combined with a 
gain of activity by sensitive cells. With initial conditions 
corresponding to 0.1 % or 1 % of resistant cells, after an 
initial phase during the first treatment, the growth rates 
of the cell population tend to become analogous. The 
main observation is that transfers significantly decreased 
the growth rate of the whole cell population exposed to 
cytotoxics, especially when the co-culture is initiated 
Figure 8. Computer simulation giving the consequences of cell-to-cell P-gp activity transfers in co-cultures exposed to doxorubicin, 
according to the mathematical model.  
A chemotherapy regimen is simulated by cyclic exposure of an inoculum of 104 cells to 1 µM doxorubicin. The treatment cycled every 14 
days, with 10 days of doxorubicin treatment followed by 4 days of interruption, for 4 cycles. The initial proportions of resistant MCF-7/DOXO 
vary form 0,1 % (A & B)  to 1 % (C & B). Simulations were performed in situations where transfers were abolished (A & C) or permitted (B 
& D) with the parameters determined in Figure 6. For each condition, the numbers of sensitive, resistant and total cells are plotted versus time. 
Sensitive MCF-7 are defined as cells having negative growth rate in the presence of 1 µM doxorubicin (see Figure 7).  
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with a relative large proportion (1 %) of resistant cells.  
 
4. DISCUSSION 
 
In the present work, we observe effective transfers 
of P-gp and efflux activity from a P-gp overexpressing 
MCF-7 variant, selected for its resistance towards 
doxorubicin, to the parental sensitive cell line. Our 
results confirm the work of Levchenko et al. (2005) 
conducted in vivo and also in vitro on several cell lines, 
including MDR1-transfected MCF-7. In 2008, the 
ability of stromal ovarian cells to confer 
chemoresistance, through heterocellular interactions and 
membrane exchanges, has also been reported and 
identified as "oncologic trogocytosis" in reference to 
analogous cell-to-cell protein transfers occurring in 
"immunological synapses" involving T cells [24]. In 
2009, a functional transfer of P-gp between acute 
MDR+ leukemic cells cultured in suspension and their 
co-cultured sensitive counterpart variant has also been 
found [25]. To our best knowledge, the present work 
and the three above cited references are the first reports 
describing extragenetic direct cell-to-cell transfers of P-
gp. Among these lines, it should be mentioned that an 
intercellular transfer of the drug resistance phenotype 
was first reported indirectly in a pioneering study of 
Frankfurt et al. [30]. 
The present data highly reinforce the fact that the P-
glycoprotein, a 170 kDa polypeptide consisting of 1280 
amino acids that spans 12 times the cell membrane [31], 
can be exchanged from a donor tumoral cell to a 
recipient one, keeping its ability to efflux drugs and, 
thus, conferring the MDR phenotype. In addition to the 
discovery of the ability, for cells, to transfer huge 
integral membrane proteins, these important findings 
also reveal the occurrence of an additional extragenetic 
mechanism to acquired chemoresistance, in the absence 
of pressure selection. The present data also increase the 
list of cells capable of protein transfers. 
The particular spatial organization of MCF-7 in co-
cultures has certainly severe consequences on the 
contact surfaces between sensitive and resistant cells. 
As seen under microscopic observation, cells were not 
organized as a homogeneous mixture of well-separated 
cell variants, but rather in delimited islets of sensitive 
settling aside from resistant cells. As a result, transfers 
between the most separated populations in term of 
chemoresistance (full sensitive versus full resistant 
cells) may occur only at the frontier of islets, keeping in 
mind that transfers can also arise between cells of 
intermediate P-gp levels. From this, it is assumed that 
the transfer process is a rather complicated phenomenon 
in which spatial structures bring limitations. As a matter 
of fact, our approach to quantify the parameters of 
transfers by using biomathematical modelling, points 
out some constraints, revealed by the parameters fitted 
to the biological data. The mathematical model has been 
constructed to i) be applicable to a population of 
interacting cells in proliferation, ii) to consider the cell 
population as a continuum density structured by the 
quantity p of transferable P-gp activity and iii) to have 
rules governing transfer. The rules of the transfer 
process have been delineated and discussed in detail in a 
companion paper [26]. The better fit was obtained by 
using the activity transferred from resistant to sensitive 
cells, undirected and directed shifts being neglected. 
Herein, we consider that P-gp activity is a better 
estimation of therapy resistance as compared to P-gp 
expression, because activity is directly responsible for 
resistance to cytotoxic drugs. Moreover, this choice 
allows us to use directly the model to simulate the 
response of a co-culture to chemotherapeutic cycles (see 
below). Nevertheless, a correlation between P-gp levels 
and activity has been described in several cell lines [15, 
32, 33]. Parameters fitting revealed quantitative aspects 
of P-gp activity transfer, in particular a transfer rate τ 
corresponding to one event every 2.5 days, a value to be 
compared to the doubling time of MCF-7 close to 1 day. 
In addition, the calculation of the average activity and 
the average level of P-gp expression over the time in a 
co-culture showed that theses values remain stable 
throughout the experiments. We conclude that there is 
neither significant gain nor loss of efflux activity and P-
gp expression during the co-culture experiments. As a 
consequence, the changes in the fluorescence 
distributions (for both P-gp and activity) can be 
attributed to transfers, which are not rare phenomena 
compared to the cell cycle duration. However, in a 
culture of growing cells transferring P-gp, the topology 
of the exchange network is constantly changing. This 
aspect is not taken into consideration in the transfer 
model which does not adapt rules of transfer as a 
function of time. The estimation of the transfer rate τ is 
therefore a coarse estimation that should be re-evaluated 
in future works including spatial dynamics.  
The model gives also a transfer efficiency f = 20 %, 
corresponding to the amount of activity transferred each 
time with regard to the absolute activity difference 
between the donor and recipient cells, and two transfer 
thresholds, that can be viewed as bottom and top 
activities delimiting authorized transfers. These 
parameters can be related to the life span of potential 
transfer vectors, that are constructed and destroyed for 
instance, or to the size of single P-gp cargos. Concerning 
this point, it has been shown that high density P-gp 
microdomains alter local properties of lipid membrane 
environment and promote P-gp clustering [34]. In this 
respect, biological data as well as modelized transfer 
parameters suggest an organized quantal transfer of P-
gp. Several intercellular carriers have been proposed to 
be involved in P-gp transfers. In adherent cells lines, 
close contacts between donor and recipient cells have 
been shown to be required [23, 24]. On the other, in a 
model of liquid tumor, P-gp containing microparticles 
released by resistant cells and bound to sensitive cells, 
have been isolated [25]. The possibility that both 
mechanisms actually co-exist in our cell line is examined 
in an independent study [27]. 
 
The model was used to simulate and to quantify the 
consequences of P-gp activity transfers on the cell 
distribution within a growing co-culture during exposure 
cycles to cytotoxics. More precisely, the model was fed 
with biological data corresponding to sensitivity of 
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MCF-7 variants to doxorubicin. Doxorubicin is among 
the preferred agents used in chemotherapy regimens for 
preoperative breast tumor reduction, adjuvant treatment 
after a first line surgical lumpectomy/mastectomy and 
radiotherapy of invasive breast carcinoma or systemic 
treatment of recurrent or metastatic breast cancers [35]. 
Doxorubicin is administrated alone or in combinations 
with other cytotoxics. In the present simulations, the 
concentration of doxorubicin was set at 1 µM, a value 
corresponding to the weekly supplementation of MCF-
7/DOXO culture medium. This concentration is also 
close to the levels of doxorubicin found in tumors under 
chemotherapy, reported to vary in the 0,1-10 µM range 
depending on the time separating the injection to the 
measures [36-38]. 
The major consequence of P-gp activity transfers is 
that subpopulations of sensitive and resistant cells were 
no longer compartmentalized. Via P-gp activity 
transfers, flows of cells depopulate and repopulate 
resistant and sensitive cells. This was obvious once the 
second cycle of treatment began, where the population 
of sensitive cells increased by adjunction of cells 
coming from resistant cells, which lose P-gp activity. 
Conversely, sensitive cells acquired P-gp activity and, 
thus, developed progressively positive growth rates 
during the treatment phases. When the number of donor 
cells was increased up to 1 %, the resulting exchanges 
of P-gp caused a significant loss of activity for the 
resistant cells. Acquisition of P-gp activity was 
therefore slowed down for sensitive cells. As a result, in 
that case, the numbers of sensitive and resistant cells 
within the co-culture converged (became close) with 
time and the overall growth rate of the cell population 
was reduced (compared to all the other situations), 
giving a co-culture with fewer cells at the end of the 
four chemotherapeutic cycles. In our model, the gain of 
P-gp is central for survival and growth of non P-gp 
expressing cells whereas the loss of P-gp by resistant 
cells has predominant effects on the overall growth rate 
of the simulated tumour.  We also conclude that the 
initial proportion of resistant cells in a population has a 
great influence on the growth of the whole population in 
the presence of transfer. 
 
The present study sheds new light on fundamental 
features underlying extragenetic acquisition of multidrug 
resistance in vitro, with a particular attention given to 
quantitative aspects. Globally, P-gp transfers led to an 
integration of the responses to the drug across the cell 
population and a 'collective' phenotype different than the 
sum of parts. However, MCF-7/DOXO represents an 
extreme case of P-gp overexpression and fast growing 
cells. Future work should be conducted with cells 
expressing intermediate amounts of efflux activity, since 
transfers have been demonstrated to be dependent on the 
P-gp levels [23].  Moreover, an improved mathematical 
model taking into account evolving 2D or 3D spatial 
considerations has to be developed together. 
Physiopathological implications of cell-to-cell protein 
transfers may be crucial, especially if other membrane 
proteins and various cell types are concerned. 
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